SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin

Jong Shiaw Jin, Tang Yi Tsao, Pei Chang Sun, Cheng Ping Yu, Ching Tzao

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We studied the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, on colon cancer. The expression of HDACs in colorectal cancer specimens and the effects of SAHA on colon cancer cells and tumors of nude mice were assessed. Treatment with SAHA (3 μm) for 72 h induced downregulation of different subtypes of HDAC proteins and also induced acetylation of histone 3 and histone 4. SAHA significantly inhibited the expression of the oncogenic protein c-myc and also increased the expression of the p53 and Rb proteins. The immunohistochemical staining of HDACs, including HDAC1, HDAC2, HDAC3, and HDAC4, was significantly increased in colorectal adenocarcinoma specimens compared to healthy control tissues. In addition, murine studies showed that 100 mg/kg SAHA administered by intraperitoneal injection significantly induced tumor necrosis and inhibited the growth of colon tumors. Immunohistochemistry of the tumor tissues from nude mice revealed that SAHA inhibited the expression of different subtypes of histone deacetylase, the anti-apoptotic proteins cyclin D1, survivin, and also inhibited cell proliferative as determined by Ki67 expression. SAHA inhibited the growth of colon tumors by decreasing histone deacetylases and the expression of cyclin D1 and survivin in nude mice.

Original languageEnglish
Pages (from-to)713-720
Number of pages8
JournalPathology and Oncology Research
Volume18
Issue number3
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Fingerprint

Histone Deacetylases
Cyclin D1
Colon
Growth
Neoplasms
Nude Mice
Histones
Colonic Neoplasms
Proto-Oncogene Proteins c-myc
Retinoblastoma Protein
Apoptosis Regulatory Proteins
Histone Deacetylase Inhibitors
Acetylation
vorinostat
Intraperitoneal Injections
Colorectal Neoplasms
Adenocarcinoma
Necrosis
Down-Regulation
Immunohistochemistry

Keywords

  • Colon cancer
  • Histone deacetylase
  • Histone deacetylase inhibitor
  • Nude mice

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. / Jin, Jong Shiaw; Tsao, Tang Yi; Sun, Pei Chang; Yu, Cheng Ping; Tzao, Ching.

In: Pathology and Oncology Research, Vol. 18, No. 3, 07.2012, p. 713-720.

Research output: Contribution to journalArticle

Jin, Jong Shiaw ; Tsao, Tang Yi ; Sun, Pei Chang ; Yu, Cheng Ping ; Tzao, Ching. / SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. In: Pathology and Oncology Research. 2012 ; Vol. 18, No. 3. pp. 713-720.
@article{63b26c06364841cca8e32fc0b1b32f77,
title = "SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin",
abstract = "We studied the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, on colon cancer. The expression of HDACs in colorectal cancer specimens and the effects of SAHA on colon cancer cells and tumors of nude mice were assessed. Treatment with SAHA (3 μm) for 72 h induced downregulation of different subtypes of HDAC proteins and also induced acetylation of histone 3 and histone 4. SAHA significantly inhibited the expression of the oncogenic protein c-myc and also increased the expression of the p53 and Rb proteins. The immunohistochemical staining of HDACs, including HDAC1, HDAC2, HDAC3, and HDAC4, was significantly increased in colorectal adenocarcinoma specimens compared to healthy control tissues. In addition, murine studies showed that 100 mg/kg SAHA administered by intraperitoneal injection significantly induced tumor necrosis and inhibited the growth of colon tumors. Immunohistochemistry of the tumor tissues from nude mice revealed that SAHA inhibited the expression of different subtypes of histone deacetylase, the anti-apoptotic proteins cyclin D1, survivin, and also inhibited cell proliferative as determined by Ki67 expression. SAHA inhibited the growth of colon tumors by decreasing histone deacetylases and the expression of cyclin D1 and survivin in nude mice.",
keywords = "Colon cancer, Histone deacetylase, Histone deacetylase inhibitor, Nude mice",
author = "Jin, {Jong Shiaw} and Tsao, {Tang Yi} and Sun, {Pei Chang} and Yu, {Cheng Ping} and Ching Tzao",
year = "2012",
month = "7",
doi = "10.1007/s12253-012-9499-7",
language = "English",
volume = "18",
pages = "713--720",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin

AU - Jin, Jong Shiaw

AU - Tsao, Tang Yi

AU - Sun, Pei Chang

AU - Yu, Cheng Ping

AU - Tzao, Ching

PY - 2012/7

Y1 - 2012/7

N2 - We studied the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, on colon cancer. The expression of HDACs in colorectal cancer specimens and the effects of SAHA on colon cancer cells and tumors of nude mice were assessed. Treatment with SAHA (3 μm) for 72 h induced downregulation of different subtypes of HDAC proteins and also induced acetylation of histone 3 and histone 4. SAHA significantly inhibited the expression of the oncogenic protein c-myc and also increased the expression of the p53 and Rb proteins. The immunohistochemical staining of HDACs, including HDAC1, HDAC2, HDAC3, and HDAC4, was significantly increased in colorectal adenocarcinoma specimens compared to healthy control tissues. In addition, murine studies showed that 100 mg/kg SAHA administered by intraperitoneal injection significantly induced tumor necrosis and inhibited the growth of colon tumors. Immunohistochemistry of the tumor tissues from nude mice revealed that SAHA inhibited the expression of different subtypes of histone deacetylase, the anti-apoptotic proteins cyclin D1, survivin, and also inhibited cell proliferative as determined by Ki67 expression. SAHA inhibited the growth of colon tumors by decreasing histone deacetylases and the expression of cyclin D1 and survivin in nude mice.

AB - We studied the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, on colon cancer. The expression of HDACs in colorectal cancer specimens and the effects of SAHA on colon cancer cells and tumors of nude mice were assessed. Treatment with SAHA (3 μm) for 72 h induced downregulation of different subtypes of HDAC proteins and also induced acetylation of histone 3 and histone 4. SAHA significantly inhibited the expression of the oncogenic protein c-myc and also increased the expression of the p53 and Rb proteins. The immunohistochemical staining of HDACs, including HDAC1, HDAC2, HDAC3, and HDAC4, was significantly increased in colorectal adenocarcinoma specimens compared to healthy control tissues. In addition, murine studies showed that 100 mg/kg SAHA administered by intraperitoneal injection significantly induced tumor necrosis and inhibited the growth of colon tumors. Immunohistochemistry of the tumor tissues from nude mice revealed that SAHA inhibited the expression of different subtypes of histone deacetylase, the anti-apoptotic proteins cyclin D1, survivin, and also inhibited cell proliferative as determined by Ki67 expression. SAHA inhibited the growth of colon tumors by decreasing histone deacetylases and the expression of cyclin D1 and survivin in nude mice.

KW - Colon cancer

KW - Histone deacetylase

KW - Histone deacetylase inhibitor

KW - Nude mice

UR - http://www.scopus.com/inward/record.url?scp=84863939925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863939925&partnerID=8YFLogxK

U2 - 10.1007/s12253-012-9499-7

DO - 10.1007/s12253-012-9499-7

M3 - Article

C2 - 22270866

AN - SCOPUS:84863939925

VL - 18

SP - 713

EP - 720

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -